Kohler Can Access Data and Pictures from Toilet Camera It Describes as “End-to-End Encrypted”

In October Kohler launched Dekota, a $600 (plus monthly subscription) device that attaches to the rim of your toilet and collects images and data from inside, promising to track and provide insights on gut health, hydration, and more. To allay the obvious privacy concerns, the company emphasizes the sensors are only pointed down, into the bowl, and assures potential buyers that the data collected by the device and app are protected with “end-to-end encryption”.

Kohler Health’s homepage, the page for the Kohler Health App, and a support page all use the term “end-to-end encryption” to describe the protection the app provides for data. Many media outlets included the claim in their articles covering the launch of the product.

However, responses from the company make it clear that—contrary to common understanding of the term—Kohler is able to access data collected by the device and associated application. Additionally, the company states that the data collected by the device and app may be used to train AI models.

[…]

emails exchanged with Kohler’s privacy contact clarified that the other “end” that can decrypt the data is Kohler themselves: “User data is encrypted at rest, when it’s stored on the user’s mobile phone, toilet attachment, and on our systems.  Data in transit is also encrypted end-to-end, as it travels between the user’s devices and our systems, where it is decrypted and processed to provide our service.”

They additionally told me “We have designed our systems and processes to protect identifiable images from access by Kohler Health employees through a combination of data encryption, technical safeguards, and governance controls.”

What Kohler is referring to as E2EE here is simply HTTPS encryption between the app and the server, something that has been basic security practice for two decades now, plus encryption at rest.

[…]

Source: Kohler Can Access Data and Pictures from Toilet Camera It Describes as “End-to-End Encrypted” – /var/log/simon

Subaru Owners Are Ticked About In-Car Pop-Up Ads for SiriusXM

I’ve written about Stellantis brands doing this twice already in 2025, and this time, it’s Subaru sending pop-up ads for SiriusXM to owners’ infotainment screens.

The Autopian ran a story on the egregious push notifications on Monday, and it only took a short search to find more examples. It happened right around Thanksgiving, as the promotion urged drivers to “Enjoy SiriusXM FREE thru 12/1.” That day has come and gone, but not before it angered droves of Subaru owners.

“I have got this Sirius XM ad a few times over the last couple of years,” the caption on the embedded Reddit thread reads. “This last time was the final straw as I almost wrecked because of it. My entire infotainment screen changed which caused me to take my eyes off the road and since I was going 55mph in winter I swerved a bit and slid and almost went off into a ditch. Something that would not have happened had this ad not popped up.

[…]

At least one 2024 Crosstrek owner reported that the pop-up took over their screen even though they were using Apple CarPlay. To force-close an application that’s in use, solely for the sake of in-car advertising, is especially egregious.

[…]

Reddit posts dating back as far as 2023 show owners complaining about in-car notifications.

[…]

 

Source: Subaru Owners Are Ticked About In-Car Pop-Up Ads for SiriusXM

New Baldness Drug Boosted Hair Growth by 168% – 539% in Trials

[…] On Wednesday, Cosmo Pharmaceuticals announced the results of its two phase III trials testing out the topical drug clascoterone for AGA. Compared to placebo, people on clascoterone gained back significantly more hair—with one trial showing a roughly 500% improvement in hair restoration. The results will pave the way for a potential FDA approval next year, which could make clascoterone the first truly novel treatment for pattern baldness seen in decades.

First-in-class

Male pattern baldness is primarily caused by having genes that make a person’s hair follicles overly sensitive to androgens (male-related sex hormones), particularly the hormone dihydrotestosterone (DHT).

There are effective medications for AGA, such as minoxidil (the active ingredient in Rogaine) and finasteride, as well as other interventions like hair transplants. But these treatments have all their potential drawbacks (including cost) or may not work for everyone.

Cosmo is hoping that clascoterone can become the first of a new class of hair loss drugs. The topical drug is an androgen receptor inhibitor, meaning it directly targets the hormones that help cause the loss of hair follicles in AGA. The Dublin-based company also argues that clascoterone isn’t systemically absorbed by the body, minimizing the risk of potential side effects.

Its two pivotal trials involved nearly 1,500 male patients diagnosed with AGA. The volunteers were randomized to receive a placebo or a topical clascoterone 5% solution on affected parts of their scalp. Both trials met their primary goal. In one, clascoterone users experienced a 539% improvement in the amount of hair grown relative to placebo, while in the other, there was a 168% improvement. According to the company, however, the absolute amount of regrown hair seen during the trials was similar between the two treatment groups. Clascoterone also appeared to be safe and tolerable, the company said, with most adverse events recorded during the studies not related to the drug itself.

[…]

Source: New Baldness Drug Boosted Hair Growth by 539% in Trials